Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
February 18 2020 - 8:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announces the appointment of Gavin
Wood as Chief Financial Officer (CFO), effective April 1, 2020.
“I am delighted to welcome Gavin to Adaptimmune. He is an
experienced and seasoned finance leader with a track record of
growing biotech companies in the UK and the US that scaled up
successfully and delivered significant value,” said Adrian
Rawcliffe, Adaptimmune’s Chief Executive Officer. “Gavin will be a
valuable addition to our leadership team, as we prepare to
commercialize our first treatment in 2022. The experience he brings
from successful commercial companies will be particularly useful to
realize our vision of an integrated cell therapy company for people
with cancer.”
Since 2006, Gavin has held CFO and senior management roles in
public companies in the life sciences sector. Most recently, he
served as the CFO and a director of Abcam plc (LSE: ABC) from
September 2016 through February 3, 2020, working as part of the
executive team that led the company through a period of significant
growth and change. Before that, Gavin held a series of roles at
Affymetrix Inc, (Nasdaq: AFFX) from 2006 to 2016, including serving
as Executive Vice President and Chief Financial Officer from May
2013 through March 2016, and managing the global finance, IT,
internal audit and facilities functions, until the company was
acquired by ThermoFisher Scientific. Gavin Wood is a Chartered
Accountant and holds a B.A. degree in Archaeology from the
University of Durham, U.K.
Michael Garone, who is serving as Interim CFO, will step down on
March 31, 2020.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for cancer patients. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T‑cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors. For more
information, please visit http://www.adaptimmune.com.
Adaptimmune Forward-Looking StatementsThis
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 6, 2019, and our other SEC filings. The
forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements
to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024